PepsiCo, Inc. (PEP)
NASDAQ: PEP · Real-Time Price · USD
154.10
-1.34 (-0.86%)
At close: Apr 27, 2026, 4:00 PM EDT
154.12
+0.02 (0.01%)
After-hours: Apr 27, 2026, 4:00 PM EDT

PepsiCo Earnings Call Transcripts

Fiscal Year 2026

Fiscal Year 2025

  • Accelerated affordability and innovation initiatives are driving volume and shelf space gains, with strong brand restaging and productivity funding growth. International and North American segments are expected to accelerate, supported by acquisitions and targeted investments.

  • Status Update

    Management outlined ambitious 2026 guidance, emphasizing productivity, innovation, and affordability to drive growth, especially in North America Foods. Capital allocation remains disciplined, with CapEx below 5% of net revenue and free cash flow conversion expected to exceed 90% by 2027.

  • Top-line growth is accelerating, driven by innovation, portfolio reshaping, and operational improvements, with margin expansion expected in Q4 and 2026. International and PBNA segments are key contributors, while cost optimization and technology investments support agility.

  • Accelerated productivity and cost optimization are driving margin gains, with strong international growth and a focus on portfolio innovation and away-from-home channels. The outlook targets sequential top-line improvement and a return to long-term growth rates.

  • AGM 2025

    The meeting highlighted resilient financial performance, with revenue and EPS growth, a 5% dividend increase, and continued investment in innovation and sustainability. All director nominees and proposals from management passed, while shareholder proposals on sweeteners, equity, biodiversity, and plastics did not.

  • Q1 2025 saw solid international growth and margin gains in North America Beverages, but FLNA volumes declined and full-year earnings guidance was reduced due to tariffs and macro uncertainty. Portfolio innovation, cost management, and international investment remain key priorities.

  • Revenue and profit growth have been driven by portfolio innovation, digital transformation, and international expansion. Focus areas include health-oriented reformulations, functional and multicultural products, and integrated infrastructure, with long-term targets of mid-single digit organic growth and high single-digit EPS growth.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Powered by